|
ORF cDNA clones
|
CRISPR / TALEN
|
Lentivirus
|
AAV
|
TALE-TF
|
ORF knockin clones
|
|
Antibody
|
Proteins
|
miRNA target clones
|
qPCR primers
|
shRNA clones
|
miRNA products
|
Promoter clones
|
Validated All-in-One™ qPCR Primer for EZH2(NM_004456.4) Search again
Product ID:
HQP095626
(click here to view gene annotation page)
Powered by BiozSpecies:
Human
Symbol:
Alias:
ENX-1, ENX1, EZH2b, KMT6, KMT6A, WVS, WVS2
Gene Description:
enhancer of zeste 2 polycomb repressive complex 2 subunit
Target Gene Accession:
NM_004456.4(click here to view gene page)
Estimated Delivery:
Approximately 1-3 weeks, but may vary. Please email sales@genecopoeia.com or call 301-762-0888 to confirm ETA.
Important Note:
By default, qPCR primer pairs are designed to measure the expression level of the splice variant (accession number) you selected for this gene WITHOUT consideration of other possible variants of this gene. If this gene has multiple variants, and you would like to measure the expression levels of one particular variant, multiple variants, or all variants, please contact us for a custom service project at inquiry@genecopoeia.com.
Summary
This gene encodes a member of the Polycomb-group (PcG) family. PcG family members form multimeric protein complexes, which are involved in maintaining the transcriptional repressive state of genes over successive cell generations. This protein associates with the embryonic ectoderm development protein, the VAV1 oncoprotein, and the X-linked nuclear protein. This protein may play a role in the hematopoietic and central nervous systems. Two transcript variants encoding distinct isoforms have been identified for this gene. [provided by RefSeq].
Gene References into function
- is overexpressed in hormone-refractory, metastatic prostate cancer; may be involved in the progression of prostate cancer, as well as being a marker that distinguishes indolent prostate cancer from those at risk of lethal progression
- functional role of EZH2 in cancer cell invasion and breast cancer progression
- essential for the proliferation of both transformed and non-transformed human cells
- deregulated expression of EZH2 is associated with loss of differentiation and development of poorly differentiated breast cancer in humans
- Ezh2 competes with HDAC1 in binding to pRb2/p130, disrupting their occupancy on the cyclin A promoter.
- Different EZH2-containing complexes target methylation of histones or nucleosomal histones
- Activated p53 suppresses EZH2 expression, suggesting a further role for p53 in epigenetic regulation and in the maintenance of genetic stability.
- hDAB2IP gene is a target gene of Ezh2 in prostatic epithelium, which provides an underlying mechanism of the down-regulation of hDAB2IP gene in prostate cancer
- The findings of this study indicate that EZH2 mRNA expression was upregulated in human HCC and may play an important role in tumour progression, especially by facilitating portal vein invasion.
- Results show the existence of the cytosolic Ezh2-containing methyltransferase complex and tie the function of this complex to regulation of actin polymerization in various cell types.
- Deregulated expression of EZH2 is associated with bladder carcinoma.
- results imply that Akt regulates the methylation activity, through phosphorylation of EZH2, which may contribute to oncogenesis
- EZH2 is essential for BMI1 recruitment to the polycomb bodies.
- A link between EZH2, a regulator of homeotic gene expression, and recombination DNA repair.
- EZH2 is required for DNA methylation of EZH2-target promoters; results suggest that EZH2 serves as a recruitment platform for DNA methyltransferases
- Increased EZH2 expression correlates with oncogenesis of the bladder.
- Findings indicate an important relationship not only between EZH2 and markers of tumor cell proliferation but also with aggressive disease.
- A fraction of late-stage tumors contains the gene amplification leading to the overexpression of the EZH2 gene, thus indicating the importance of EZH2 in the progression of prostate cancer
- EZH2 is important for the maintenance of circadian rhythms and has a role in the core clockwork mechanism of mammals
- We summarize the current knowledge on the function of EZH2 in cancer, with special focus on breast cancer, and propose a link between EZH2, the homologous recombination pathway of DNA repair, and breast tumorigenesis.
- Advanced cell- & animal imaging, expression profiling, stable siRNA-gene targeting, and TMAs of experimental and clinical samples indicate that activation of the Ezh2 oncogene-associated PcG pathway plays an essential role in metastatic prostate cancer.
- Review. EZH2 is up-regulated in ductal carcinoma in situ, atypical ductal hyperplasia, and even morphologically normal breast epithelial cells from women who have an increased risk of breast cancer. EZH2 may promote neoplastic conversion.
- PcG protein EZH2 is associated with adverse pathological features and clinical PSA recurrence of prostate cancer.
- Our data disclose a hitherto unexplored link between the putative oncogene EZH2 and the tumor suppressor PSP94, and show that MSMB is silenced by EZH2 in advanced prostate cancer cells.
- Ezh2 has a role in aging of the hematopoietic stem cell system [review]
- Study shows that the ability of the oncogene BMI1 to repress the INK4A-ARF locus requires its direct association and is dependent on the continued presence of the EZH2-containing Polycomb-Repressive Complex 2 complex.
- EZH2 regulates the transcription of estrogen-responsive genes through association with REA, an estrogen receptor corepressor
- These experiments indicated that EZH2 is a dual function transcription regulator with a dynamic activity, and we provide a mechanism for EZH2 in tumorigenesis.
- APAF-1 methylation is related to transcriptional activity of EZH2 expression in early-stage tumor disease of the bladder.
- Expressed target cancer genes with minimal DNA methylation have increased transcription during EZH2 knockdown, densely DNA hypermethylated and silenced genes retain their methylation and remain transcriptionally silent.
- EZH2 plays a key role in hepatocellular carcinoma tumorigenesis, and is a novel therapeutic target.
- EZH2 protein levels increase incrementally from benign nevi to melanoma, which suggests that EZH2 may play a role in the pathogenesis and progression of melanoma
- The comprehensive downstream pathways of EZH2 were determined by proteomic profiling.
- EZH2 expression levels were correlated to pathological tumor features and outcome in patients with urothelial carcinoma of the bladder.
- NIPP1 is present in a complex with EED and EZH2 in vivo and has distinct binding sites for these proteins.
- EZH2 is involved in transcriptional down-regulation of interferon gamma-induced MHC class II transactivator (CIITA) expression in uveal melanoma.
- ADRB2 inhibition confers cell invasion and transforms benign prostate epithelial cells, whereas ADRB2 overexpression counteracts EZH2-mediated oncogenesis
- EZH2 may regulate actin polymerization dynamics and thereby promote prostate cancer cell motility and invasiveness.
- Data show that EZH2 mRNA expression in circulating epithelial cells represents a promising marker for detecting early metastasis in prostate cancer.
- EZH2 expression was associated with decreased survival of patients with basal-like phenotype of breast cancer.
- PHF1 modulates the activity of Ezh2 in favor of the repressive H3K27me3 mark
- This study provides into the mechanisms underlying the functional role of EZH2 overexpression in gastric cancer cells and a new modality of regulation of E-cadherin expression in silencing mechanisms of tumor suppressor genes.
- Overexpression of EZH2 is associated with primary prostate carcinoma
- RUNX3 is a target for repression by EZH2 in gastric cancer cells
- EZH2 mediates histone H3 lysine 27 trimethylation as a mechanism of tumor-suppressor gene silencing in cancer that is potentially independent of promoter DNA methylation
- A direct mediator of long-range intra- and interchromosomal interactions that can regulate transcriptional down-regulation of multiple genes by facilitating physical proximities between distant chromatin regions
- overexpression associated with the malignant progression of hepatocellular carcinoma
- EZH2 gene plays a role for both the proliferation and the apoptosis resistance of renal cell carcinoma cells
- the two PRC2 components SUZ12 and EZH2 are sumoylated in vitro and in vivo
- Expression changes in EZH2 are associated with DNA methylation in prostate cancer.
- MYC stimulates EZH2 expression by repression of its negative regulator miR-26a
- Repression of E-cadherin by the polycomb group protein EZH2 in cancer is reported.
- EZH2 nuclear overexpression contributes to pancreatic cancer cell proliferation.
- study proposes that the genomic loss of miR-101 in cancer leads to overexpression of EZH2 and concomitant dysregulation of epigenetic pathways, resulting in cancer progression
- EZH2 maintains repressive chromatin through different mechanisms.
- E7 target gene EZH2 is a major determinant for the proliferation of HPV-positive cancer cells and contributes to their apoptotic resistance.